60 Degrees Pharma

05/18/2026

This study isn’t just focused on treatment, it’s also looking closely at diagnostics.

By using multiple testing methods, the goal is to confirm infection using FDA-aligned standards, while evaluating how well existing diagnostics perform.

This kind of validation could help improve how babesiosis is detected and monitored in the future.

Link in bio to find out more: https://60degreespharma.com/infectious-diseases/babesiosis/

05/14/2026

Babesiosis can affect more than you’d expect.

Because it targets red blood cells, it can disrupt how oxygen moves through the body, which means the effects aren’t limited to one system.

Symptoms like fatigue, air hunger, and brain fog can all show up together, and not always in a way that clearly points to the underlying infection.

Learn more about ongoing babesiosis clinical research: https://60degreespharma.com/infectious-diseases/babesiosis/

05/13/2026

Reported case counts are only part of the story.

Lyme disease was once reported at a fraction of its estimated prevalence before surveillance methods improved.

As babesiosis cases continue to rise, it raises a familiar question about how much current data is capturing – and more importantly – how much may still be unaccounted for.

Learn more about what we’re seeing around babesiosis case numbers: https://investors.60degreespharma.com/news-releases/news-release-details/babesiosis-incidence-us-10x-higher-cdc-estimates-according

05/12/2026

Such important information from Global Lyme Alliance

Emergency room visits for tick bites have climbed to the highest levels for this time of year since 2017.

05/11/2026

It took seven years to get an accurate diagnosis, and another seven to regain her health.
That’s a long time to live without clear answers.
desjardins.15 shares her experience, and why she now focuses on helping others better understand vector-borne illness, and the different ways people can approach healing.

It’s an important reminder of why more research in this space is so important – and why we’re focused on pushing it forward.

Full episode here: https://podcasts.apple.com/ni/podcast/the-silver-lyming-episode-73-with-dr-geoffrey-dow/id1701323635?i=1000724455874&l=en-GB

05/11/2026

Babesiosis may be far more common than the initial numbers suggest.

Survey data from indicates cases could be undercounted by as much as 25× – with an estimated 46,000 U.S. cases annually, compared to 1,834 reported by the CDC.
Improving both clinical awareness and improving diagnostic sensitivity is essential to understanding the true scope of disease burden – particularly for stealth pathogens like Babesia.

We’re committed to helping move that progress forward.

05/07/2026

Tick-borne diseases are becoming more visible across the U.S. – both in reported data and geographic spread.

As case numbers increase, so does the need for continued research into how these infections behave, overlap, and evolve over time.

There’s still more to learn, and we’re working hard to understand it.

Find out how we’re supporting research in the babesiosis space: https://60degreespharma.com/infectious-diseases/babesiosis/

05/06/2026

For many patients, the conversation starts with Lyme disease.

But ticks don’t always carry just one pathogen.

Research suggests co-infections are far more common than they’re routinely accounted for in diagnosis.

Looking beyond a single infection may change how cases are understood.

Learn more about ongoing babesiosis clinical research: https://60degreespharma.com/infectious-diseases/babesiosis/

05/04/2026

Lyme disease didn’t become widely recognized overnight.

For years, symptoms were misunderstood, case counts were underestimated, and research was limited.

Babesia shares some of those same patterns today – common in patients, but not always top of mind in diagnosis or discussion.

The question is… Are we catching it earlier this time, or repeating the same cycle?

Find out more about the work we’re doing in this space: https://60degreespharma.com/infectious-diseases/babesiosis/

05/01/2026

Standard thinking: if you’re otherwise healthy, acute babesiosis resolves with treatment.

But what about patients whose immune systems aren’t functioning the same way?

Dr. Dow spoke to about the gap in research for patients with immune dysregulation, including those with long COVID, chronic fatigue syndrome, and post-treatment Lyme disease.

This is the group we know the least about, and the one that may need answers the most.

04/30/2026

Despite growing awareness, there is still a lack of long-term, objective research in chronic babesiosis.

As Dr. Dow highlights, this presents a critical challenge – not only for understanding the disease, but for guiding patient care.

The issue isn’t a lack of need. It’s a lack of data.

We’re working to change that.